Citation 104205

ZHU,M: PHILLIPSON,JD: GREENGRASS,PM: BOWERY,NE: CAI,Y:. (1997). PLANT POLYPHENOLS:BIOLOGICALLY ACTIVE COMPOUNDS OR NON-SELECTIVE BINDERS TO PROTEIN?. 44(3)

Citation Details

Title	PLANT POLYPHENOLS:BIOLOGICALLY ACTIVE COMPOUNDS OR NON-SELECTIVE BINDERS TO PROTEIN?
Authors	ZHU,M: PHILLIPSON,JD: GREENGRASS,PM: BOWERY,NE: CAI,Y:
Year	1997
Volume	44
Issue	3

Summary

Year: 1997

Journal: Unknown

Organisms and Their Experiments (1)

Unknown organism

Experiment #	Pharmacology Type	Worktypes	Compound	Results
1	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
2	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
3	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
4	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
5	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
6	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
7	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
8	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
9	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
10	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
11	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
12	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
13	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
14	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	INACTIVE
15	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	EQUIVOCAL
16	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,(+):	WEAK ACTIVITY
17	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
18	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
19	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
20	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
21	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
22	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
23	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
24	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
25	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
26	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
27	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
28	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
29	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	INACTIVE
30	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
31	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
32	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,(+):	EQUIVOCAL
33	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	INACTIVE
34	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
35	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	INACTIVE
36	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	ACTIVE
37	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	WEAK ACTIVITY
38	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
39	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	INACTIVE
40	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	INACTIVE
41	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
42	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
43	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
44	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	ACTIVE
45	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
46	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	INACTIVE
47	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
48	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN-3-O-GALLATE	EQUIVOCAL
49	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
50	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
51	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
52	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
53	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
54	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
55	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
56	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
57	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
58	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
59	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
60	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	INACTIVE
61	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
62	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
63	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	EQUIVOCAL
64	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	AFZELECHIN,EPI:	ACTIVE
65	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
66	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
67	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
68	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
69	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
70	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
71	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
72	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
73	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
74	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
75	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	INACTIVE
76	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
77	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	WEAK ACTIVITY
78	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
79	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	EQUIVOCAL
80	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	CATECHIN,EPI: (-):	ACTIVE
81	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	INACTIVE
82	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
83	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
84	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
85	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	STRONG ACTIVITY
86	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
87	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	INACTIVE
88	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	INACTIVE
89	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
90	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
91	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	INACTIVE
92	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
93	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	WEAK ACTIVITY
94	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
95	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
96	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN,EPI: (-):	EQUIVOCAL
97	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
98	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
99	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
100	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	WEAK ACTIVITY
101	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
102	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
103	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
104	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
105	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
106	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
107	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
108	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	WEAK ACTIVITY
109	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
110	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	INACTIVE
111	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
112	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOCATECHIN-3-O-GALLATE,EPI: (-):	EQUIVOCAL
113	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	INACTIVE
114	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	INACTIVE
115	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
116	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
117	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	STRONG ACTIVITY
118	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	WEAK ACTIVITY
119	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	INACTIVE
120	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	INACTIVE
121	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
122	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
123	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
124	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
125	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
126	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
127	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
128	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-2	EQUIVOCAL
129	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	INACTIVE
130	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
131	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
132	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
133	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	STRONG ACTIVITY
134	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
135	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	INACTIVE
136	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	INACTIVE
137	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
138	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
139	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	INACTIVE
140	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
141	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
142	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
143	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
144	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-3	EQUIVOCAL
145	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
146	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	WEAK ACTIVITY
147	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
148	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
149	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	STRONG ACTIVITY
150	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
151	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
152	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
153	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
154	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
155	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
156	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	INACTIVE
157	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
158	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	WEAK ACTIVITY
159	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	WEAK ACTIVITY
160	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	WEAK ACTIVITY
161	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	PROCYANIDIN B-4	EQUIVOCAL
162	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
163	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
164	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
165	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	ACTIVE
166	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	WEAK ACTIVITY
167	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
168	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
169	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
170	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
171	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
172	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
173	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
174	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
175	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	INACTIVE
176	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
177	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,2-4-DI-O:	EQUIVOCAL
178	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
179	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
180	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
181	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	WEAK ACTIVITY
182	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
183	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
184	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
185	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
186	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
187	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
188	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
189	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
190	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	INACTIVE
191	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
192	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	EQUIVOCAL
193	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:	ACTIVE
194	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-6-TRI-O:GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
195	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
196	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
197	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	ACTIVE
198	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
199	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
200	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
201	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
202	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
203	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
204	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
205	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
206	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	WEAK ACTIVITY
207	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	INACTIVE
208	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	EQUIVOCAL
209	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-3-6-TRI-O:	ACTIVE
210	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
211	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	EQUIVOCAL
212	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
213	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	WEAK ACTIVITY
214	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
215	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	EQUIVOCAL
216	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
217	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
218	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
219	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	EQUIVOCAL
220	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
221	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	EQUIVOCAL
222	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	ACTIVE
223	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	INACTIVE
224	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	ACTIVE
225	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-4-6-TETRA-O:	EQUIVOCAL
226	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
227	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	EQUIVOCAL
228	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
229	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	ACTIVE
230	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
231	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
232	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
233	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
234	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	EQUIVOCAL
235	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	EQUIVOCAL
236	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
237	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	WEAK ACTIVITY
238	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	WEAK ACTIVITY
239	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	INACTIVE
240	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	WEAK ACTIVITY
241	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GALLOYL-BETA-D-GLUCOSE,1-2-3-4-6-PENTA-O:	EQUIVOCAL
242	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
243	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
244	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
245	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	WEAK ACTIVITY
246	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
247	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
248	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
249	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
250	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
251	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
252	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	INACTIVE
253	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
254	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
255	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
256	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
257	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	TELLIMAGRANDIN I	EQUIVOCAL
258	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
259	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	EQUIVOCAL
260	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
261	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	WEAK ACTIVITY
262	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
263	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	EQUIVOCAL
264	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
265	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
266	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
267	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	EQUIVOCAL
268	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
269	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	EQUIVOCAL
270	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	EQUIVOCAL
271	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	INACTIVE
272	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	WEAK ACTIVITY
273	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	PEDUNCULAGIN	ACTIVE
274	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
275	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	EQUIVOCAL
276	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
277	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	ACTIVE
278	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
279	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	EQUIVOCAL
280	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	EQUIVOCAL
281	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	EQUIVOCAL
282	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
283	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
284	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
285	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	EQUIVOCAL
286	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	WEAK ACTIVITY
287	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	INACTIVE
288	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	WEAK ACTIVITY
289	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	DAVIDIIN	WEAK ACTIVITY
290	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
291	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	EQUIVOCAL
292	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	EQUIVOCAL
293	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	EQUIVOCAL
294	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	WEAK ACTIVITY
295	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
296	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
297	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
298	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
299	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
300	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	INACTIVE
301	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	ACTIVE
302	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	EQUIVOCAL
303	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	WEAK ACTIVITY
304	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	GERANIIN	EQUIVOCAL
305	ATP-ASE (NA+/K+) BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
306	SPHINGOMYELINASE INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
307	BENZODIAZEPINE BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
308	OPIATE RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
309	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
310	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
311	SEROTONIN (5-HT) RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
312	MUSCARINIC RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
313	CALCIUM CHANNEL BINDING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
314	SULFONYLUREA RECEPTOR BINDING ACTIVITY	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
315	ADENOSINE A-1 RECEPTOR BINDING INHIBITION	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
316	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	WEAK ACTIVITY
317	DOPAMINE RECEPTOR BLOCKING EFFECT	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	INACTIVE
318	ADRENERGIC RECEPTOR BLOCKER(ALPHA-1)	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	EQUIVOCAL
319	ADRENERGIC RECEPTOR BLOCKER(ALPHA-2)	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	ACTIVE
320	ADRENERGIC RECEPTOR BLOCKER(BETA)	PHARMACOLOGY OF COMPOUND - IN VITRO	RUGUSIN D	WEAK ACTIVITY

Citation 104205

Citation Details

Summary

Organisms and Their Experiments (1)

Unknown organism

Show SPARQL Queries (1)

Query 1